Compare Mesoblast Limited (MESO) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs 22nd Century Group Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Mesoblast Limited is far larger — about 1456.4× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| MESO | XXII | |
|---|---|---|
Market Cap | $2.17B | $1.49M |
Sector | Technology | Technology |
52-Week High | $20.96 | $1.07K |
52-Week Low | $12.88 | $3.90 |
Enterprise Value | $2.17B | -$6.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.
While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
